All Updates

All Updates

icon
Filter
Product updates
ArteraAI announces predictive AI biomarker for androgen deprivation therapy
Precision Medicine
Jun 29, 2023
This week:
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Funding
OceanWell raises USD 11 million in Series A funding to build water farms
Conservation Tech
Yesterday
Product updates
H launches Runner H, an AI agent for business automation
Foundation Models
Yesterday
Partnerships
Capgemini partners with Mistral AI and Microsoft to expand GenAI solutions globally
Foundation Models
Yesterday
Funding
Product updates
Converge Bio launches biotech LLM platform with USD 5.5 million seed funding
Foundation Models
Yesterday
Partnerships
Snowflake partners with Anthropic to integrate Claude AI models into Cortex AI platform
Foundation Models
Yesterday
Product updates
DeepSeek releases AI reasoning model DeepSeek-R1
Foundation Models
Yesterday
Industry news
Partnerships
ICEYE partners with Lockheed Martin and Finnish firms to develop defense space technologies
Next-gen Satellites
Yesterday
Partnerships
Dematic installs AutoStore system at South West Healthcare logistics hub
Logistics Tech
Yesterday
Precision Medicine

Precision Medicine

Jun 29, 2023

ArteraAI announces predictive AI biomarker for androgen deprivation therapy

Product updates

  • Bioinformatics company ArteraAI has recently released data that validates the first-ever predictive AI biomarker for assessing the benefits of androgen deprivation therapy (ADT) in prostate cancer. ADT is a treatment often used in combination with radiotherapy, but it is associated with known adverse effects.

  • The newly developed biomarker aids in the identification of patients that are more likely to benefit from androgen deprivation therapy (ADT), facilitating personalized treatment strategies. The study employed deep-learning techniques and analyzed histopathology image data from over 5,000 patients participating in five Phase III randomized trials. This milestone study involved patients from multiple centers in the US and Canada, representing a significant advancement in the field of prostate cancer treatment.

  • California-based Artera is a precision medicine company that is working on AI tests with the aim of customizing treatment options for patients suffering from cancer. The company’s flagship test is a test to identify patients that will benefit from therapy intensification and help guide treatment decisions for men with localized prostate cancer. The test is clinically available through a single CLIA-certified laboratory in Jacksonville, Florida, and costs USD 3,873.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.